SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vimta Labs gets nod for foray into biologics CDMO business

29 Apr 2025 Evaluate

Vimta Labs has received approval for foray into biologics contract research and development activities (CDMO). The estimated amount to be invested is Rs 50 crore. The foray into this new segment will help the company to enter into the growing CDMO business of biologics and peptides, that will strengthen its service portfolio to biopharmaceutical industry, enabling acceleration of its business growth. The board of directors of the company in its meeting held on April 28, 2025, has approved the same.

Vimta Labs is India’s leading contract research and testing organization.

Vimta Labs Share Price

474.50 -15.75 (-3.21%)
12-May-2026 13:03 View Price Chart
Peers
Company Name CMP
Syngene Internation. 482.00
Indegene 533.15
CMS Info Systems 304.10
JITF Infralogistics 315.00
Sagility 43.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×